Qulipta vs Vyepti
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Qulipta | US Vyepti | |
|---|---|---|
| Generic name | atogepant | eptinezumab |
| Drug class | CGRP Receptor Antagonist | Anti-CGRP Monoclonal Antibody |
| Treats | Migraine prevention | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | AbbVie | Lundbeck |
| Year approved | 2021 | 2020 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $120M | — |
| Common side effects | Nausea, Constipation, Fatigue, Decreased appetite | Stuffy nose and sore throat, Allergic reactions, Fatigue |
Frequently asked questions
Is Qulipta or Vyepti better?
Neither is universally "better." Qulipta (atogepant) and Vyepti (eptinezumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Qulipta and Vyepti?
Qulipta is a CGRP Receptor Antagonist made by AbbVie, while Vyepti is a Anti-CGRP Monoclonal Antibody made by Lundbeck. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Qulipta has the larger estimated TV advertising budget of the two.